The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura

Karagöz, Filiz; BARIŞ, Sancar; KEFELİ, Mehmet; KANDEMİR, Bedri; YILDIZ, Levent; Gun, Seda

The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura

Seda GÜN, (Mehmet Aydın Eğitim ve Araştırma Hastanesi, Samsun, Türkiye)

Bedri KANDEMİR, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Samsun, Türkiye)

Mehmet KEFELİ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Samsun, Türkiye)

Levent YILDIZ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Samsun, Türkiye)

Sancar BARIŞ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Samsun, Türkiye)

Filiz KARAGÖZ (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Samsun, Türkiye)

Türk Patoloji Dergisi

2 0

Yıl: 2010 Cilt: 26 Sayı: 3 Sayfa Aralığı: 189 - 195 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura

Öz:

Amaç: En son pozitif mezotelyal belirleyici olarak tanımlanan podoplanin ve D2-40'ın malign mezotelyoma ile primer akciğer adenokarsinomu ve plevraya metastaz yapan adenokarsinomların ayırımında taşıdığı değeri araştırmak.Gereç ve Yöntem: Ondokuz Mayıs Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı'nda 1988-2008 yılları arasında malign mezotelyoma tanısı almış 11 olgu ve buna eş sayıda primer akciğer adenokarsinomu, bronkioloalveoler karsinom, plevranın metastatik karsinomları ve mezotelyal proliferasyon tanısı almış toplam 55 olguya D2-40, podoplanin, kalretinin, sitokeratin 5/6, karsinoembriyonik antijen, epitelyal spesifik antijen (MOC- 31) ile immünhistokimyasal çalışma yapıldı. Boyanma yaygınlığı 1+ ile 4+ arasında derecelendirildi.Bulgular: D2-40 ile 11 mezotelyoma olgusunun 7'si (%63,6), mezotelyal proliferasyon olgusunun 10'u (%90,9) pozitif boyanırken primer akciğer adenokarsinomu, bronkioloalveoler karsinom ve plevranın metastatik karsinomu olgularında pozitiflik görülmedi. Podoplanin ile mezotelyoma olgularının 9'u (%81,8), mezotelyal proliferasyon olgularının 10'u (%90,9) pozitif boyanırken diğer gruplarda pozitiflik görülmedi. Primer akciğer adenokarsinomlarının sekizi (%72.7), bronkioloalveoler karsinomların yedisi (%63.6), plevranın metastatik karsinomlarının sekizi (%72.7), MOC-31 ile reaksiyon verirken, mezotelyoma olgularının sadece birinde pozitif boyanma görüldü; mezotelyal proliferasyon olgularının hiçbirinde reaksiyon izlenmedi. Mezotelyoma için podoplanin, D2-40 ve kalretinin ve sitokeratin 5/6'nın özgüllükleri %100 bulundu. Duyarlılıkları ise sırasıyla %,81,8, %63,6, %81,8, %54,5 idi. Mezotelyoma için en yüksek yani % 100 duyarlılık, D2-40, podoplanin ve kalretinin kombinasyonu kullanıldığında saptandı.Sonuç: D2-40 ve Podoplanin'in malign mezotelyoma ile primer akciğer adenokarsinomları, bronkioloalveoler karsinom ve plevranın metastatik karsinomlarının ayırımında etkin olduğu, ancak kesin sonuçlar vermediği; bu nedenle bu belirleyicilerin de içinde yer aldığı pozitif ve negatif mezotelyal belirleyiciler ile bir panel oluşturulmasının daha doğru sonuçlara ulaştırabileceği kanısına varıldı.

Anahtar Kelime:

Konular: Cerrahi

D2-40 ve podoplanin'in mezotelyomaların akciğerin primer adenokarsinomları ve plevranın metastatik karsinomlarından ayrımındaki rolü

Öz:

Objective: The aim of this study was to assess the diagnostic and differential significance of two recently introduced positive mesothelial markers, namely podoplanin and D2-40.Material and Method: The study group included a total of 55 cases: 11 cases of malignant mesothelioma and equal number of cases (n:11) of primary lung adenocarcinoma, bronchioloalveolar carcinoma, metastatic carcinoma of the pleura and mesothelial proliferation. D2- 40, podoplanin, calretinin, cytokeratin 5/6, carcinoembryonic antigen, epithelial specific antigen (MOC-31) were immunohistochemically studied in all cases. The extent of staining was graded between 1+ and 4+.Results: While the 7 (63.6%) of the mesotheliomas and 10 of the mesothelial proliferations (90.9%) stained positive with D2-40, no positive staining was noted in primary lung adenocarcinoma, bronchioloalveolar carcinoma, metastatic carcinoma of the pleura. 9 of the mesotheliomas (81.8%) and 10 of the mesothelial proliferations (90.9%) were positive with podoplanin whereas no positive staining was observed in the other groups. Eight of the primary lung adenocarcinomas (72.7%), seven of the bronchioloalveolar carcinomas (63.6%), and eight of the metastatic carcinomas of the pleura (72.7%) were positive for MOC-31 while only one of the mesotheliomas (9%) was positive and no mesothelial proliferation cases were positive. The specificity of podoplanin, D2-40, calretinin and cytokeratin 5/6 for mesothelioma was 100% and their sensitivity was 81.8%, 63.6%, 81.8% and 54.5%, respectively. The highest sensitivity, (i.e. 100% sensitivity) for mesothelioma was observed with the D2-40, podoplanin, and calretinin combination.Conclusion: D2-40 and Podoplanin were effective in differentiating malignant mesothelioma from primary lung adenocarcinomas, bronchioloalveolar carcinoma and metastatic carcinomas of the pleura. However, since they may not yield precise results it was therefore concluded that a panel combined with positive and negative mesothelial markers including these two markers will lead to more accurate results.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1) Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17: 260-271
2) Weiss SW, Goldblum JR: Mesothelioma. In Weiss SW, Goldblum JR (Eds): Enzinger & Weiss’s Soft Tissue Tumors. 5th, St Louis Mosby, 2008, 789-823
3) Ordóñez NG: The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003, 27: 1031- 1051
4) King JE, Thatcher N, Pickering CA, Hasleton PS: Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006, 48: 223–232
5) Abutaily AS, Addis BJ, Roche WR: Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002, 55: 662–668
6) Comin CE, Novelli L, Boddi V, Paglierani M, Dini S: Calretinin thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001, 32: 529- 536
7) Ordóñez NG: Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005, 129: 1407– 1414
8) Ordóñez NG: What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007, 38: 1–16
9) Carella R, Deleonardi G, D’Errico A, Salerno A, Egarter-Vigl E Seebacher C, Donazzan G, Grigioni WF: Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001, 25: 43–50
10) Ordóñez NG: Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002, 33: 953-967
11) Ordóñez NG: D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005, 36: 372- 380
12) Oates J, Edwards C: HBME-1,MOC-31, WT-1 and calretinin : an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000, 36: 341-347
13) Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ: Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005, 18: 105–110
14) Kimura N, Kimura I: Podoplanin as a marker for mesothelioma. Pathol Int 2005, 55: 83-86
15) Ordóñez NG: The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006, 19: 34 - 48
16) Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE: The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985, 121: 235-247
17) Chu PG, Weiss LM: Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002, 15: 6-10
18) Wang NS, Huang SN, Gold P: Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers. Cancer 1979, 44: 937 – 943

APA	Gun S, KANDEMİR B, KEFELİ M, YILDIZ L, BARIŞ S, Karagöz F (2010). The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. , 189 - 195.
Chicago	Gun Seda,KANDEMİR Bedri,KEFELİ Mehmet,YILDIZ Levent,BARIŞ Sancar,Karagöz Filiz The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. (2010): 189 - 195.
MLA	Gun Seda,KANDEMİR Bedri,KEFELİ Mehmet,YILDIZ Levent,BARIŞ Sancar,Karagöz Filiz The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. , 2010, ss.189 - 195.
AMA	Gun S,KANDEMİR B,KEFELİ M,YILDIZ L,BARIŞ S,Karagöz F The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. . 2010; 189 - 195.
Vancouver	Gun S,KANDEMİR B,KEFELİ M,YILDIZ L,BARIŞ S,Karagöz F The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. . 2010; 189 - 195.
IEEE	Gun S,KANDEMİR B,KEFELİ M,YILDIZ L,BARIŞ S,Karagöz F "The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura." , ss.189 - 195, 2010.
ISNAD	Gun, Seda vd. "The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura". (2010), 189-195.

APA	Gun S, KANDEMİR B, KEFELİ M, YILDIZ L, BARIŞ S, Karagöz F (2010). The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. Türk Patoloji Dergisi, 26(3), 189 - 195.
Chicago	Gun Seda,KANDEMİR Bedri,KEFELİ Mehmet,YILDIZ Levent,BARIŞ Sancar,Karagöz Filiz The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. Türk Patoloji Dergisi 26, no.3 (2010): 189 - 195.
MLA	Gun Seda,KANDEMİR Bedri,KEFELİ Mehmet,YILDIZ Levent,BARIŞ Sancar,Karagöz Filiz The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. Türk Patoloji Dergisi, vol.26, no.3, 2010, ss.189 - 195.
AMA	Gun S,KANDEMİR B,KEFELİ M,YILDIZ L,BARIŞ S,Karagöz F The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. Türk Patoloji Dergisi. 2010; 26(3): 189 - 195.
Vancouver	Gun S,KANDEMİR B,KEFELİ M,YILDIZ L,BARIŞ S,Karagöz F The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura. Türk Patoloji Dergisi. 2010; 26(3): 189 - 195.
IEEE	Gun S,KANDEMİR B,KEFELİ M,YILDIZ L,BARIŞ S,Karagöz F "The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura." Türk Patoloji Dergisi, 26, ss.189 - 195, 2010.
ISNAD	Gun, Seda vd. "The role of D2–40, and podoplanin in differentiating mesotheliomas from primary adenocarcinomas of the lung and metastatic carcinomas of the pleura". Türk Patoloji Dergisi 26/3 (2010), 189-195.